JANICE R MCCLUNE
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner LANCASTER, PA NPI 1487019170
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner PA NOVARTIS PHARMACEUTICALS CORPORATION All categories
General Payments — all program years on this page
$1,410.81
- Category: General Payments
- Program years: PY2021–2024
- Record count: 52
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $942.94 across 41 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $942.94 | 41 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $83.16 | 4 |
| Janssen Biotech, Inc. | $52.67 | 2 |
| Lilly USA, LLC | $49.22 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $49.11 | 2 |
| Merck Sharp & Dohme Corporation | $48.95 | 2 |
| Celgene Corporation | $46.80 | 3 |
| E.R. Squibb & Sons, L.L.C. | $42.85 | 2 |
| Genentech USA, Inc. | $41.00 | 2 |
| GENZYME CORPORATION | $38.92 | 1 |
| JAZZ PHARMACEUTICALS INC. | $38.41 | 1 |
| GlaxoSmithKline, LLC. | $35.52 | 2 |
| Astellas Pharma US Inc | $28.56 | 1 |
| EMD Serono, Inc. | $27.87 | 1 |
| Alexion Pharmaceuticals, Inc. | $26.76 | 1 |
| Adaptive Biotechnologies Corporation | $26.30 | 1 |
| Genmab U.S., Inc. | $25.29 | 1 |
| Kyowa Kirin, Inc. | $24.04 | 1 |
| Stemline Therapeutics Inc. | $23.50 | 1 |
| EISAI INC. | $23.20 | 1 |
| Pharmacosmos Therapeutics Inc. | $22.90 | 1 |
| TAIHO ONCOLOGY, INC. | $22.80 | 1 |
| PharmaEssentia USA Corporation | $22.77 | 1 |
| Ipsen Biopharmaceuticals, Inc | $22.76 | 1 |
| TerSera Therapeutics LLC | $21.04 | 1 |
| SOBI, INC | $20.21 | 1 |
| Deciphera Pharmaceuticals Inc. | $20.16 | 1 |
| Acerta Pharma LLC | $20.07 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $19.45 | 1 |
| Incyte Corporation | $18.65 | 1 |
By program year
Records — PY2024 (41)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.